Government prosecutors in the criminal-fraud trial of Theranos's former second-in-command, Ramesh “Sunny” Balwani, made their final pitch to the jury in closing arguments Tuesday
Government lawyer says Ramesh ‘Sunny’ Balwani gave investors false financial projections; defense counsel says U.S. left out crucial evidence
Elizabeth Holmes's former top deputy at Theranos, Ramesh ‘Sunny’ Balwani, faces charges of defrauding investors and patients about the startup’s blood-testing capabilities, which he denies. Photo: Getty ImagesGovernment prosecutors in the criminal-fraud trial of Theranos Inc.’s former second-in-command, Ramesh “Sunny” Balwani, made their final pitch to the jury in closing arguments Tuesday, as the Silicon Valley case moves closer to a resolution.
Assistant U.S. Attorney Jeff Schenk said that Mr. Balwani, longtime president and chief operating officer of the now-defunct blood-testing startup, had full knowledge of the fraud he was committing because he was in charge of Theranos’s laboratory and was well-informed of its many problems with test accuracy and reliability—and fired employees who raised concerns.